Get the Stockscreener App
1.17
0.86%
0.01
Metagenomi Therapeutics Inc stock is traded at $1.17, with a volume of 54,793.
It is up +0.86% in the last 24 hours and down -3.31% over the past month.
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
See More
Previous Close:
$1.16
Open:
$1.14
24h Volume:
54,793
Relative Volume:
0.33
Market Cap:
$44.20M
Revenue:
$22.33M
Net Income/Loss:
$-85.89M
P/E Ratio:
-0.51
EPS:
-2.2942
Net Cash Flow:
$-89.47M
1W Performance:
-1.68%
1M Performance:
-3.31%
6M Performance:
-26.88%
1Y Performance:
-34.27%
1-Day Range:
$1.14
$1.1702
1-Week Range:
$1.1281
$1.21
52-Week Range:
$1.1281
$3.95
Metagenomi Therapeutics Inc Stock (MGX) Company Profile
Name
Metagenomi Therapeutics Inc
Sector
Industry
Phone
(510) 871-4880
Address
5959 HORTON STREET, EMERYVILLE
Compare MGX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGX
Metagenomi Therapeutics Inc
|
1.17 | 45.33M | 22.33M | -85.89M | -89.47M | -2.2942 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Metagenomi Therapeutics Inc Stock (MGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Initiated | H.C. Wainwright | Buy |
| May-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-05-24 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-24 | Initiated | Chardan Capital Markets | Buy |
| Mar-05-24 | Initiated | JP Morgan | Overweight |
| Mar-05-24 | Initiated | Jefferies | Buy |
| Mar-05-24 | Initiated | TD Cowen | Outperform |
| Mar-05-24 | Initiated | Wells Fargo | Overweight |
View All
Metagenomi Therapeutics Inc Stock (MGX) Latest News
Metagenomi Therapeutics (MGX) Holds Steady at $1.23 as Biotech Consolidates Between Key LevelsBreakout Stock Alerts - vinanet.vn
Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Analysts Are Cutting Their Estimates: Here's What You Need To Know - simplywall.st
These Analysts Think Metagenomi Therapeutics, Inc.'s (NASDAQ:MGX) Sales Are Under Threat - webull.com
Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR) - The Globe and Mail
Metagenomi Therapeutics reports $27.5M loss in Q2 2026 - scanx.trade
Metagenomi Therapeutics (MGX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Metagenomi Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Metagenomi Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Metagenomi Therapeutics (MGX) revenue drops as losses widen but cash tops $120M - Stock Titan
Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results - The Manila Times
Metagenomi Therapeutics Inc expected to post a loss of 57 cents a shareEarnings Preview - TradingView
MGX Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue ChallengesQuarterly Earnings - vinanet.vn
Metagenomi Therapeutics (MGX) Edges Higher as Gene-Editing Speculation PercolatesBreakaway Gap - Vinanet
Amazon has Q2 sales of $200bn - Electronics Weekly
MGX Q1 2026 Earnings: EPS Miss Reflects Operational Progress in Gene Editing PipelineManagement Tone Analysis - Vinanet
Metagenomi Therapeutics (MGX) Proxy filing Summary - Quartr
Metagenomi Therapeutics (MGX) AGM 2026 Summary - Quartr
Metagenomi Therapeutics (MGX) Q1 2026 earnings summary - Quartr
Metagenomi Therapeutics (MGX) Slides 2.7% as Stock Tests Key Support LevelTICK Divergence - vinanet.vn
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - AOL.com
Chardan Capital Initiates Metagenomi Therapeutics(MGX.US) With Buy Rating, Announces Target Price $5 - Moomoo
Chardan initiates Metagenomi stock with buy, $5 target on gene therapy potential - Investing.com
Metagenomi Therapeutics (MGX) Faces Continued Pressure Near Support LevelsSchiff Line - po-news-eg.net
Metagenomi Therapeutics (MGX) Holds Steady at $1.25 as Stock Consolidates Between Key LevelsSingle Stock ETF - dars.gov.et
Metagenomi Therapeutics (MGX) Rebounds from Support, Eyes Resistance at $1.31Price Surge Stocks - dars.gov.et
Price to sales forward of Metagenomi Therapeutics, Inc. – NASDAQ:MGX - TradingView
Enterprise value to EBIT forward of Metagenomi Therapeutics, Inc. – NASDAQ:MGX - TradingView
Price to book forward of Metagenomi Therapeutics, Inc. – NASDAQ:MGX - TradingView
Price to earnings forward of Metagenomi Therapeutics, Inc. – NASDAQ:MGX - TradingView
Metagenomi Therapeutics, Inc. Actuals & Estimates (NASDAQ:MGX) - TradingView
MGX Forecast — Price Target — Prediction for 2027 - TradingView
Metagenomi Therapeutics (MGX) Edges Lower, Testing Key Support at $1.13Sign of Strength - dars.gov.et
MGX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Metagenomi Therapeutics Inc. (MGX) Q1 2026 Earnings: Wider-Than-Expected Loss Amid Continued Pipeline InvestmentDividend Increase Stocks - dars.gov.et
Metagenomi Therapeutics (MGX) Rebounds from Support; Faces Key Resistance at $1.26Sign of Weakness - dars.gov.et
Metagenomi Therapeutics (MGX) Edges Lower as Stock Tests Key Support ZoneBull Pennant - Město Břeclav
Metagenomi Therapeutics (MGX) director awarded 17,400 stock options at $1.23 - Stock Titan
Metagenomi Therapeutics (MGX) director awarded options on 21,000 shares - Stock Titan
Metagenomi Therapeutics (MGX) director receives 21,000-share stock option grant at $1.23 - Stock Titan
Metagenomi (NASDAQ: MGX) director receives 21,000 stock options at $1.23 strike - Stock Titan
Metagenomi CFO Pamela Wapnick sells $3,746 of company stock - Investing.com UK
Metagenomi CEO Jian Irish sells $4,854 in company stock - Investing.com UK
Metagenomi general counsel Wein sells $724 in common stock - Investing.com UK
Metagenomi CFO Pamela Wapnick sells $3,746 of company stock By Investing.com - Investing.com Australia
[Form 4] Metagenomi Therapeutics, Inc. Insider Trading Activity - Stock Titan
Tax-driven sale as Metagenomi (MGX) director Irish reports 3,737 shares sold - Stock Titan
Metagenomi Announces Board Changes and Shareholder Meeting Results - TipRanks
Metagenomi Therapeutics, Inc. Announces Resignation of Brian C. Thomas, Ph.D. as A Member of the Board, Effective as of June 9, 2026 - marketscreener.com
Brian C. Thomas resigns from Metagenomi board effective June 9, 2026 - TradingView
Metagenomi (NASDAQ: MGX) director exits as shareholders back board - Stock Titan
MGX: Directors and auditor were approved, with no stockholder questions or new nominations - TradingView
Metagenomi Therapeutics Inc Stock (MGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Metagenomi Therapeutics Inc Stock (MGX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Irish Jian | See Remarks |
Jun 05 '26 |
Sale |
1.30 |
3,737 |
4,854 |
377,533 |
| Wein Matthew | See Remarks |
Jun 05 '26 |
Sale |
1.30 |
558 |
725 |
126,491 |
| Wapnick Pamela | Chief Financial Officer |
Mar 05 '26 |
Sale |
1.60 |
1,581 |
2,530 |
187,375 |
| Wein Matthew | See Remarks |
Mar 05 '26 |
Sale |
1.60 |
482 |
771 |
114,549 |
| Irish Jian | Chief Executive Officer |
Mar 05 '26 |
Sale |
1.60 |
1,607 |
2,571 |
333,770 |
| Thomas Brian C. | Director |
Dec 05 '25 |
Sale |
1.77 |
3,830 |
6,786 |
2,510,960 |
| Wein Matthew | See Remarks |
Dec 05 '25 |
Sale |
1.77 |
199 |
353 |
115,031 |
| Wapnick Pamela | Chief Financial Officer |
Dec 05 '25 |
Sale |
1.77 |
1,576 |
2,793 |
188,956 |
| Irish Jian | Chief Executive Officer |
Dec 05 '25 |
Sale |
1.77 |
1,602 |
2,839 |
563,839 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):